Ketamine and Addiction: A Complex Picture
Using ketamine — itself a substance with documented addiction potential — to treat substance use disorders is one of the more counterintuitive areas of ketamine research. Yet a growing body of preclinical and clinical work suggests that ketamine may have specific therapeutic mechanisms relevant to addiction treatment, particularly for alcohol and cocaine use disorders.
This is an emerging area with genuine promise but also significant cautions. Patients and providers must approach ketamine-assisted treatment for substance use disorders with both open minds and significant rigor. A thorough review of contraindications is especially important in this population.
Proposed Mechanisms for Addiction Treatment
Reconsolidation Disruption for Drug Memories
Addiction involves deeply encoded associative memories — cue-triggered cravings arise when drug-associated stimuli (locations, people, emotions, paraphernalia) reactivate drug memories. These memories guide drug-seeking behavior even in people who are highly motivated to abstain.
As with PTSD treatment, ketamine's NMDA receptor blockade may disrupt the reconsolidation of drug-related memories when they are retrieved during treatment. By blocking reconsolidation during a controlled session in which drug cues are briefly activated, ketamine may weaken the motivational pull of these memories.
Neuroplasticity and Prefrontal Restoration
Chronic substance use damages prefrontal cortical function, impairing the executive control and inhibitory processes that normally regulate impulsive behavior and substance seeking. Ketamine's BDNF-mediated synaptogenesis may help restore prefrontal function, improving the neural substrate of self-control.
Antidepressant Effects Addressing Comorbidity
Depression and anxiety are among the most powerful drivers of relapse in substance use disorders. Negative affect is a primary trigger for use. Ketamine's rapid antidepressant and anxiolytic effects address this dimension directly — if negative emotional states are reduced, the motivational drive to self-medicate with alcohol or other substances decreases.
Anti-Craving Effects
Some clinical reports suggest that ketamine produces reductions in craving that outlast its acute pharmacological effects. The mechanism is not fully understood but may relate to NMDA receptor changes, neuroplasticity effects, or the psychological impact of the dissociative experience on rigid motivational patterns.
Alcohol Use Disorder: The Best Evidence
Alcohol use disorder (AUD) is the most studied substance use condition in ketamine research, and the evidence is most developed here.
Ketamine-Assisted Psychotherapy for AUD
The KARE (Ketamine for the Reduction of Alcoholic Relapse) program in the UK represents the most rigorous clinical work. Researchers have conducted multiple trials examining ketamine-assisted psychotherapy for AUD, with findings including:
- Significantly improved abstinence rates at 6 months compared to psychotherapy alone
- Reduced craving scores during the treatment period
- Better functional outcomes and quality of life measures
The KARE-1 and KARE-2 trials (Grabski et al., 2022 and related publications) showed that 3 sessions of IV ketamine combined with psychological therapy produced significantly higher abstinence rates at 6 months compared to lorazepam plus therapy (87% vs 23% full abstinence in the most striking preliminary data from KARE-2).
These are remarkable numbers, though they come from relatively small trials and require replication in larger studies.
Mechanism for AUD
The reconsolidation disruption hypothesis is particularly relevant for AUD — alcohol cue reactivity is a major driver of relapse. Additionally, ketamine's antidepressant effects are directly relevant to the negative affect cycle in alcohol dependence.
Cocaine and Stimulant Use Disorders
Cocaine use disorder has no FDA-approved pharmacotherapy — it is one of the most treatment-refractory addiction conditions. Ketamine's mechanisms offer theoretical promise:
- Dopamine system modulation: Cocaine hijacks dopamine reward circuitry; ketamine affects dopamine release and may help restore normal dopamine function
- Prefrontal restoration: Cocaine damages prefrontal circuits; ketamine promotes prefrontal synaptogenesis
- Reconsolidation of cocaine memories: May be disrupted by ketamine
Clinical evidence for cocaine use disorder is at an earlier stage than AUD — primarily case reports, small open-label studies, and preliminary trial data. Results are encouraging but not definitive.
Opioid Use Disorder
Ketamine's role in opioid use disorder (OUD) is primarily as a pain management adjunct — helping patients with chronic pain reduce opioid doses by addressing central sensitization. It is not a primary treatment for opioid addiction itself (methadone and buprenorphine remain the evidence-based standards).
For patients with both OUD and comorbid depression, ketamine's antidepressant effects may support OUD treatment by addressing the depressive component of craving and relapse risk.
The Significant Cautions
Ketamine Itself Has Addiction Potential
Ketamine is a Schedule III controlled substance with documented abuse liability. Street use of ketamine ("K-hole" recreational use at high doses) is a known phenomenon. For patients with active substance use disorders, prescribing a potentially addictive substance requires extraordinary care.
Before considering ketamine-assisted treatment for substance use disorders, prescribers should assess:
- Is the patient's substance use currently active and severe, or are they in recovery?
- What is the risk of ketamine becoming a substitute addiction?
- Is there a robust support system and treatment framework to prevent diversion or misuse?
Home-Based Troches Are Not Appropriate for Most SUD Patients
The at-home troche format, which requires patient self-management and secure storage of a controlled substance, is generally not appropriate for patients with active, severe substance use disorders. The risk of:
- Diversion (using more than prescribed, sharing, or selling)
- Substitute dependence (developing a ketamine use pattern)
- Impaired consent and judgment during relapse periods
...makes clinic-based administration far more appropriate for this population. If ketamine is being used to assist addiction recovery, it should generally be administered in a controlled, supervised clinical setting.
No Established Troche Protocol for SUD
There is no established, validated sublingual ketamine protocol for substance use disorders. The research that exists largely uses IV ketamine in clinical settings with structured psychotherapy. Extrapolating to home-based troches for addiction treatment is premature and potentially risky without careful clinical oversight.
Who Might Be Considered
The narrow population for whom ketamine-assisted treatment for substance use might be considered:
- Patients in stable recovery from a substance use disorder (not actively using)
- Patients with significant comorbid depression or anxiety driving relapse risk
- Patients who have engaged in and are continuing formal addiction treatment programs
- Patients who have failed standard pharmacotherapy (naltrexone, acamprosate, bupropion as applicable) and behavioral interventions
- Patients with demonstrated insight into their addiction patterns and risk factors
- Patients whose prescriber is experienced in both addiction medicine and ketamine treatment
This is a narrow population. For most people with active substance use disorders, the risks outweigh the benefits of ketamine treatment outside of specialized research settings.
Key Takeaways
- Ketamine shows genuine promise for alcohol use disorder (KARE trials), less evidence for cocaine, and limited evidence for opioids.
- Mechanisms include memory reconsolidation disruption, prefrontal restoration, and antidepressant effects addressing comorbidity.
- Ketamine itself has addiction potential — its use in SUD patients requires extraordinary care and clinical judgment.
- Home-based troches are generally not appropriate for active SUD patients; clinic-based administration with structured psychotherapy is the appropriate research-informed model.
- This is an emerging area; most evidence comes from IV ketamine in clinical settings, not sublingual troches.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
- WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches
Share